Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Agios Pharmaceuticals
Biotech
Agios says adios to sickle cell program over lackluster data
The phase 2 study of Agios’ next-generation pyruvate kinase activator failed to support continued development in sickle cell disease.
Nick Paul Taylor
Jul 21, 2026 8:30am
Agios signs $165M deal for blood disorder drug that failed study
Jun 1, 2026 9:26am
Agios’ next-gen PK drug fails ph. 2 blood cancer study
May 29, 2026 9:13am
Agios' next-up PK med quelled transfusion need in some patients
Nov 20, 2023 11:24am
Agios pays $17.5M for Alnylam's siRNA blood disease program
Aug 3, 2023 8:40am
Servier’s $1.8B bet on Agios delivers phase 3 brain tumor win
Mar 14, 2023 10:15am
